2. Search Result
Search Result
Results for "

myc+inhibitor

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12702
    10058-F4
    Maximum Cited Publications
    55 Publications Verification

    		 c-Myc Autophagy Cancer
    10058-F4 is a c-Myc inhibitor that prevents c-Myc-Max dimerization and transactivation of c-Myc target gene expression.
    10058-F4
  • HY-129600
    MYCi361
    2 Publications Verification

    NUCC-0196361

    		 c-Myc Cancer
    MYCi361 (NUCC-0196361) is a MYC inhibitor with the Kd of 3.2 μM for binding to MYC. MYCi361 (NUCC-0196361) suppresses tumor growth and enhances anti-PD1 immunotherapy .
    MYCi361
  • HY-148836
    c-Myc inhibitor 6

    		c-Myc Infection Cardiovascular Disease Cancer
    c-Myc inhibitor 6 (compound A102) is a c-Myc inhibitor. c-Myc inhibitor 6 decreases cancer cell viability and degrades c-Myc protein. c-Myc inhibitor 6 can be used for the research of c-Myc imbalance, such as cancer, cardiovascular diseases, and viral infection .
    c-Myc inhibitor 6
  • HY-122683
    sAJM589
    2 Publications Verification

    		 c-Myc Cancer
    sAJM589 is a Myc inhibitor which potently disrupts the Myc-Max heterodimer with an IC50 of 1.8 μM .
    sAJM589
  • HY-12703
    KSI-3716
    2 Publications Verification

    		 c-Myc Autophagy Cancer
    KSI-3716 is a potent c-Myc inhibitor that blocks c-MYC/MAX binding to target gene promoters. KSI-3716 is an effective intravesical chemotherapy agent for bladder cancer .
    KSI-3716
  • HY-144878
    VPC-70619
    2 Publications Verification

    		 c-Myc Cancer
    VPC-70619 is a potent N-Myc inhibitor. VPC-70619 blocks the binding of the N-Myc-Max heterocomplex to the DNA E-box and exhibits potent inhibitory activity against N-Myc-dependent cell lines. VPC-70619 can partially reverse paclitaxel (HY-B0015) resistance in cells by reducing MYCN expression. VPC-70619 can be used for cancer research (e.g., neuroblastoma and thyroid cancer) .
    VPC-70619
  • HY-124129
    10074-A4

    		c-Myc Cancer
    10074-A4 is a c-Myc inhibitor. 10074-A4 could bind to c-Myc370-409 at different sites along the peptide chain. 10074-A4 has anticancer effects .
    10074-A4
  • HY-168685
    c-Myc ligand 1

    		c-Myc Ligands for Target Protein for PROTAC Cancer
    c-Myc ligand 1, a c-Myc inhibitor, is a PROTAC target protein ligand (Ligand for Target Protein for PROTAC). c-Myc ligand 1 can be used for synthesis PROTAC c-Myc inhibitor 7 (HY-148837) .
    c-Myc ligand 1
  • HY-125978
    JY-3-094

    		c-Myc Cancer
    JY-3-094 is a Myc inhibitor that inhibits Myc-Max heterodimer formation (IC50: 33 μM) .
    JY-3-094
  • HY-148838
    c-Myc inhibitor 8

    		c-Myc Cancer
    c-Myc inhibitor 8 (compound 56) is a c-Myc inhibitor. c-Myc inhibitor 8 effectively inhibits cell viability of a variety of cancer cells. c-Myc inhibitor 8 inhibits human prostate and lung cancer growth in mouse models. c-Myc inhibitor 8 can be used for cancer research .
    c-Myc inhibitor 8
  • HY-148839
    c-Myc inhibitor 9

    		c-Myc Cancer
    c-Myc inhibitor 9 (compound 332) is a c-Myc inhibitor with an logEC50 of ≥6. c-Myc inhibitor 9 inhibits tumor growth in nude mouse models. c-Myc inhibitor 9 can be used for cancer research .
    c-Myc inhibitor 9
  • HY-155507
    c-Myc inhibitor 11

    		c-Myc Cancer
    c-Myc inhibitor 11 (Compound 67e) is a c-MYC inhibitor (pEC50: 6.4). c-Myc inhibitor 11 has high clearance levels, moderate volume of distribution and short half-life in rat pharmacokinetic assay. c-Myc inhibitor 11 can be used for cancer research .
    c-Myc inhibitor 11
  • HY-154839
    c-Myc inhibitor 10

    		c-Myc Cancer
    c-Myc inhibitor 10 (compound 17), a c-Myc inhibitor, exhibits increased cellular potency, consistent with an increase in permeability with methylation of the morpholine nitrogen .
    c-Myc inhibitor 10
  • HY-160549
    c-Myc inhibitor 14

    		c-Myc Cancer
    c-Myc inhibitor 14 (Compound 13A) is a c-Myc protein inhibitor. The IC50 value of HL60 inhibitor is <100 nM. c-Myc inhibitor 14 shows antitumor activity .
    c-Myc inhibitor 14
  • HY-162294
    c-Myc inhibitor 13

    		c-Myc Cancer
    c-Myc inhibitor 13 (compound A6) is a c-MYC transcription inhibitor. c-Myc inhibitor 13 selectively stabilizes c-MYC G4 and inhibits G4-associated c-MYC transcription .
    c-Myc inhibitor 13
  • HY-139885
    c-Myc inhibitor 4

    		c-Myc Cancer
    c-Myc inhibitor 4 is a potent, orally bioavailable c-MYC-reducing compound.
    c-Myc inhibitor 4
  • HY-145843
    c-Myc inhibitor 5

    		c-Myc Cancer
    c-Myc inhibitor 5 (DA3) is a fluorescent, long chain-bridged bispurine that selectively targets the c-MYC G-quadruplex (KD of 16 μM). c-Myc inhibitor 5 shows inhibition on c-MYC expression rather than other G4-driven oncogenes .
    c-Myc inhibitor 5
  • HY-173467
    PROTAC MTP3 degrader-1

    		PROTACs c-Myc Cancer
    PROTAC MTP3 degrade-1 is a PROTAC based MYC degrader (Red: MYC inhibitor (HY-173469), black: linker (HY-W008296), Blue: E3 ligase ligand (HY-14658)) .
    PROTAC MTP3 degrader-1
  • HY-178045
    MYC-IN-4

    		c-Myc Cancer
    MYC-IN-4 is a MYC inhibitor. MYC-IN-4 impairs MYC/MAX protein-protein interaction (IC50 = 3.06 μM). MYC-IN-4 inhibits MYC-aberrant PC-3 prostate cancer cells with an IC50 of 0.440 μM. MYC-IN-4 demonstrates potent antitumor efficacy in FVB mice bearing Myc-CaP prostate tumor allografts. MYC-IN-4 can be used for the study of prostate cancer .
    MYC-IN-4
  • HY-169921
    c-Myc inhibitor 15

    		c-Myc Apoptosis Cancer
    c-Myc inhibitor 15 (Compound A5) is a selective c-Myc inhibitor that exerts anticancer effects by disrupting the interaction between c-Myc and Max, leading to the degradation of c-Myc protein and the induction of apoptosis. Its IC50 values are 4.08 μM and 7.86 μM in A549 and NCI-H1299 lung cancer cell lines, respectively, demonstrating strong cytotoxic activity. In a syngeneic tumor model, c-Myc inhibitor 15 exhibited outstanding antitumor efficacy, achieving a tumor growth inhibition rate of 76.4% and significantly reducing c-Myc protein expression levels. c-Myc inhibitor 15 holds promise for research related to c-Myc-driven lung cancers .
    c-Myc inhibitor 15
  • HY-176066A
    c-Myc inhibitor 16 iodide

    		c-Myc Apoptosis Cancer
    c-Myc inhibitor 16 iodide (Compound W11) is a selective c-Myc G-quadruplex (c-Myc G4) inhibitor. c-Myc inhibitor 16 iodide inhibits the transcription and translation of the c-Myc gene, disrupts the tumor cell cycle, arrests cell growth in the G0/G1 phase and activates the mitochondrial apoptosis pathway to induce early apoptosis of cancer cells. c-Myc inhibitor 16 iodide is promising for research of breast cancer .
    c-Myc inhibitor 16 iodide
  • HY-155508
    c-Myc inhibitor 12

    		c-Myc Cancer
    c-Myc inhibitor 12 (compound 67h) is an inhibitor of c-Myc with a pEC50 of 6.4 .
    c-Myc inhibitor 12
  • HY-168684
    E3 Ligase Ligand-linker Conjugate 136

    		E3 Ligase Ligand-Linker Conjugates Cancer
    E3 Ligase Ligand-linker Conjugate 136 is an E3 ligase ligand-linker conjugate. E3 Ligase Ligand-linker Conjugate 136 can be used to synthesize c-Myc inhibitor 7 (HY-148837) .
    E3 Ligase Ligand-linker Conjugate 136
  • HY-149513
    EP12

    		c-Myc Apoptosis Cancer
    EP12 is a c-Myc inhibitor. EP12 is a c-Myc G4 stabilizer. EP12 induces apoptosis and DNA damage in multiple myeloma cells. EP12 disrupts the nuclear translocation of P65/P50 by interfering with the NF-κB signaling pathway. EP12 inhibits multiple myeloma growth .
    EP12
  • HY-169378
    CSI86

    		PROTACs c-Myc Cancer
    CSI86 is a MYC-targeting PROTAC degrader with antiproliferative activity (IC50: 13-18 μM) . CSI86 is composed of MYC inhibitor (red part) CSI118 TFA (HY-169379), E3 ligase ligand (blue part) VH032 (HY-120217), and PROTAC linker (black part) Succinic anhydride (HY-79369). The conjugate composed of E3 ligase ligand and linker is (S,R,S)-CO-C2-acid (HY-131866).
    CSI86
  • HY-180454
    NUCC-0201642

    		c-Myc Cancer
    NUCC-0201642 is a c-MYC inhibitor with an IC50 value greater than 40 μM. NUCC-0201642 can be used for cancer research .
    NUCC-0201642
  • HY-181473
    Antiproliferative agent-75

    		Drug Derivative c-Myc Cancer
    Antiproliferative agent-75, Pyrrole (HY-Y0807) derivative, is an antiproliferative agent with an IC50 value of 0.06 μM against Myc-driven human B-cells. Antiproliferative agent-75 can be used for the development of pyrrole-based Myc inhibitor .
    Antiproliferative agent-75
  • HY-181234
    Y502-3888

    		c-Myc Apoptosis Cancer
    Y502-3888 is a c-Myc inhibitor. Y502-3888 binds to the c-Myc G4 structure, inhibits c-Myc transcription, and downregulates c-Myc expression at both mRNA and protein levels. Y502-3888 inhibits the viability of myeloma cells and induces cell apoptosis. Y502-3888 can be used for the research of multiple myeloma .
    Y502-3888

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: